Sandbox g16: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) |
||
Line 25: | Line 25: | ||
| Antifungal agent | | Antifungal agent | ||
| | | | ||
* Mild hepatic impairment (Child-Pugh score | * Mild hepatic impairment (Child-Pugh score 5–6): no dosage adjustment is required | ||
* Moderate hepatic impairment (Child-Pugh score | * Moderate hepatic impairment (Child-Pugh score 7–9): 35 mg once daily following a 70-mg loading dose on day 1 | ||
* Severe hepatic impairment (Child-Pugh score | * Severe hepatic impairment (Child-Pugh score 10–15): no clinical experience available | ||
* Pediatric patients with any degree of hepatic impairment: dosing recommendations are not available | * Pediatric patients with any degree of hepatic impairment: dosing recommendations are not available | ||
|- | |- | ||
Line 60: | Line 60: | ||
| Antiretroviral agent | | Antiretroviral agent | ||
| | | | ||
* Mild Hepatic Impairment (Child-Pugh | * Mild Hepatic Impairment (Child-Pugh score 5–6): 700 mg twice daily without ritonavir (therapy-naive) or 700 mg twice daily plus ritonavir 100 mg once daily (therapy-naive or protease inhibitor-experienced) | ||
* Moderate Hepatic Impairment (Child-Pugh | * Moderate Hepatic Impairment (Child-Pugh score 7–9): 700 mg twice daily without ritonavir (therapy-naive), or 450 mg twice daily plus ritonavir 100 mg once daily (therapy-naive or protease inhibitor-experienced) | ||
* Severe Hepatic Impairment (Child-Pugh | * Severe Hepatic Impairment (Child-Pugh score 10–15): 350 mg twice daily without ritonavir (therapy-naive) or 300 mg twice daily plus ritonavir 100 mg once daily (therapy-naive or protease inhibitor-experienced) | ||
* Pediatric patients with any degree of hepatic impairment: dosing recommendations are not available | * Pediatric patients with any degree of hepatic impairment: dosing recommendations are not available | ||
|- | |- | ||
Line 93: | Line 93: | ||
* Patients with hepatic impairment metabolize metronidazole slowly, with resultant accumulation of metronidazole in the plasma. | * Patients with hepatic impairment metabolize metronidazole slowly, with resultant accumulation of metronidazole in the plasma. | ||
* For patients with mild to moderate hepatic impairment, no dosage adjustment is needed but these patients should be monitored for metronidazole associated adverse events. | * For patients with mild to moderate hepatic impairment, no dosage adjustment is needed but these patients should be monitored for metronidazole associated adverse events. | ||
* For patients with severe hepatic impairment (Child-Pugh C), a reduction in metronidazole dosage by 50% is recommended. | * For patients with severe hepatic impairment (Child-Pugh class C), a reduction in metronidazole dosage by 50% is recommended. | ||
|- | |- | ||
| Nafcillin | | Nafcillin | ||
Line 104: | Line 104: | ||
| | | | ||
* Nelfinavir may be used in patients with mild hepatic impairment without any dose adjustment. | * Nelfinavir may be used in patients with mild hepatic impairment without any dose adjustment. | ||
* Nelfinavir should not be used in patients with either moderate or severe hepatic impairment. | * Nelfinavir should not be used in patients with either moderate or severe hepatic impairment. | ||
|- | |- | ||
| Nevirapine | | Nevirapine | ||
| Antiretroviral agent | |||
| | |||
* Nevirapine Nis contraindicated in patients with moderate (Child-Pugh class B) or severe (Child-Pugh class C) hepatic impairment. | |||
|- | |- | ||
| style="white-space: nowrap;" | Quinupristin-Dalfopristin | | style="white-space: nowrap;" | Quinupristin-Dalfopristin |
Revision as of 04:32, 4 June 2015
Dosage adjustment in patients with hepatic disease Return to Top
Dosage adjustment may be required in the presence of hepatic disease for the following medications (consult FDA package insert for details):
Antimicrobial Agent | Drug Category | Dosing Recommendation |
---|---|---|
Abacavir | Antiviral agent |
|
Atazanavir | Antiviral agent |
|
Caspofungin | Antifungal agent |
|
Chloramphenicol | Antibacterial agent |
|
Clindamycin | Antibacterial agent |
|
Darunavir-Ritonavir | Antiviral agent |
|
Delavirdine | Antiretroviral agent |
|
Efavirenz | Antiretroviral agent |
|
Fosamprenavir | Antiretroviral agent |
|
Indinavir | Antiretroviral agent |
|
Isoniazid | Antimycobacterial agent |
|
Itraconazole | Antifungal agent |
|
Lopinavir-Ritonavir | Antiretroviral agent |
|
Metronidazole | Antibacterial agent |
|
Nafcillin | Antibacterial agent |
|
Nelfinavir | Antiretroviral agent |
|
Nevirapine | Antiretroviral agent |
|
Quinupristin-Dalfopristin | ||
Rifabutin | ||
Rifampin | ||
Rimantadine | ||
Ritonavir | ||
Telithromycin | ||
Tigecycline | ||
Tinidazole | ||
Voriconazole |